Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC002291 | Panoply™ Human CALCA Knockdown Stable Cell Line | Inquiry |
| CSC-SC002291 | Panoply™ Human CALCA Over-expressing Stable Cell Line | Inquiry |
| CLOE-0503 | Human CALCA(Fc) HEK293 Cell Lysate | Inquiry |
| CLOE-0504 | Human CALCA(His) HEK293 Cell Lysate | Inquiry |
| CSC-RO01411 | Human CALCA Stable Cell Line - HCE-T | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD02909Z | Human CALCA adenoviral particles | Inquiry |
| LV07774L | human CALCA (NM_001033953) lentivirus particles | Inquiry |
| LV07775L | human CALCA (NM_001033952) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHG136653 | shRNA set against Rat Calca(NM_001033955.1) | Inquiry |
| SHG136649 | shRNA set against Mouse Calca(NM_007587.2) | Inquiry |
| SHG136925 | shRNA set against Rat Calca(NM_017338.2) | Inquiry |
| SHG136943 | shRNA set against Rat Calca(NM_001033956.1) | Inquiry |
| SHG136961 | shRNA set against Mouse Calca(NM_001033954.3) | Inquiry |
| SHG136979 | shRNA set against Mouse Calca(NM_007587.2) | Inquiry |
| SHG136993 | shRNA set against Rat Calca(NM_001033955.1) | Inquiry |
| SHH253693 | shRNA set against Human CALCA (NM_001741.2) | Inquiry |
| SHH253697 | shRNA set against Mouse CALCA (NM_007587.2) | Inquiry |
| SHH253701 | shRNA set against Rat CALCA (NM_017338.2) | Inquiry |
| SHW002750 | shRNA set against Chicken CALCA (NM_001113708) | Inquiry |
| SHW003632 | shRNA set against Chicken CALCA (NM_001271964) | Inquiry |
| SHW003633 | shRNA set against Chicken CALCA (NM_001271965) | Inquiry |
| SHW003634 | shRNA set against Chicken CALCA (NM_001271966) | Inquiry |
| SHW006487 | shRNA set against Danio rerio CALCA (NM_001002471) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| MiUTR4H-TG10790 | CALCA miRNA 3'UTR clone | Inquiry |
| MiUTR1R-00689 | CALCA miRNA 3'UTR clone | Inquiry |
| MiUTR1R-00688 | CALCA miRNA 3'UTR clone | Inquiry |
| MiUTR1M-02467 | CALCA miRNA 3'UTR clone | Inquiry |
| MiUTR1M-02466 | CALCA miRNA 3'UTR clone | Inquiry |
| CDFR011051 | Rat Calca cDNA Clone(NM_017338.2) | Inquiry |
| CDFR004302 | Rat Calca cDNA Clone(NM_001033956.1) | Inquiry |
| CDCR040806 | Mouse Calca ORF clone (NM_001033954.3) | Inquiry |
| CDFR004299 | Rat Calca cDNA Clone(NM_001033955.1) | Inquiry |
| CDCR371328 | Rat Calca ORF Clone(NM_001033955.1) | Inquiry |
| CDFH002613 | Human CALCA cDNA Clone(NM_001741.2) | Inquiry |
| MiUTR1R-00690 | CALCA miRNA 3'UTR clone | Inquiry |
| CDCR378437 | Rat Calca ORF Clone(NM_017338.2) | Inquiry |
| CDCR371329 | Rat Calca ORF Clone(NM_001033956.1) | Inquiry |
| CDCR281410 | Human CALCA ORF Clone(NM_001741.2) | Inquiry |
| CDCL183019 | Human CALCA ORF clone(NM_001033952.2) | Inquiry |
| CDCG012573 | Mouse CALCA ORF clone(NM_007587.2) | Inquiry |
| CDCB167962 | Danio rerio CALCA ORF Clone (NM_001002471) | Inquiry |
| CDCB165109 | Chicken CALCA ORF Clone (NM_001271966) | Inquiry |
| CDCB165108 | Chicken CALCA ORF Clone (NM_001271965) | Inquiry |
| CDCB165107 | Chicken CALCA ORF Clone (NM_001271964) | Inquiry |
| CDCS406855 | Human CALCA ORF Clone (BC069760) | Inquiry |
| CDCB164225 | Chicken CALCA ORF Clone (NM_001113708) | Inquiry |
The CALCA gene, located on human chromosome 11p15.2, exemplifies the complexity and precision of eukaryotic gene expression. Through tissue-specific alternative RNA splicing, a single transcript gives rise to two distinct biologically active peptides: calcitonin (CT) and calcitonin gene-related peptide (CGRP). Additionally, post-translational proteolytic processing of the precursor protein can generate a third active peptide, katacalcin. This "one gene, multiple products" mechanism allows CALCA to perform divergent physiological roles depending on the tissue context.
In thyroid parafollicular cells, the primary transcript encodes the calcitonin precursor, which is processed into mature calcitonin. In contrast, in the nervous and cardiovascular systems, selective splicing skips the calcitonin exon, yielding CGRP, which exists in two major isoforms: α-CGRP, encoded by CALCA, and β-CGRP, encoded by the homologous CALCB gene. These isoforms have overlapping but subtly distinct functions, forming a finely tuned regulatory network. Such complex transcriptional and post-translational regulation ensures that CALCA products exert precise effects at the right time and place, underpinning their multifunctional biological roles.
CALCA gene products are involved in calcium-phosphate homeostasis, neuro-immune-vascular communication, and more. Calcitonin primarily inhibits osteoclast-mediated bone resorption, promoting calcium and phosphate deposition in bone. This acute hypocalcemic effect counterbalances parathyroid hormone, maintaining mineral metabolism.
CGRP is recognized as one of the most potent endogenous vasodilators. By binding its specific receptor, CGRP induces relaxation of coronary, cerebral, and peripheral vessels, regulating local blood flow, blood pressure, and microcirculation. In the central and peripheral nervous systems, CGRP functions as a neurotransmitter and neuromodulator, modulating pain signaling, initiating and sustaining inflammation, and regulating autonomic functions.
Figure 1. Schematic representation of a CGRP receptor. (Iyengar S, et al., 2017)
Notably, CGRP released from sensory nerve terminals triggers neurogenic inflammation, causing vasodilation, plasma protein extravasation, and mast cell degranulation-critical mechanisms in pain and inflammatory disorders. CGRP also exhibits direct antimicrobial activity, suggesting a role in innate immune defense and forming a communication link between the nervous and immune systems. Katacalcin primarily contributes to calcium homeostasis, with mechanisms and physiological significance still under investigation. Together, CALCA products serve as multifunctional regulators in bone metabolism, cardiovascular homeostasis, neural signaling, immune defense, and inflammation, with dysregulation implicated in various diseases.
The clinical importance of CALCA, particularly CGRP, is most prominent in migraine pathophysiology and treatment. During migraine attacks, abnormal activation of the trigeminovascular system leads to massive CGRP release from sensory nerve endings, causing severe intracranial vasodilation and neurogenic inflammation, producing throbbing headache and associated symptoms. This discovery established CGRP and its receptor as revolutionary therapeutic targets.
Clinically approved therapies include: CGRP receptor antagonists and monoclonal antibodies targeting CGRP or its receptor, which effectively and specifically block CGRP signaling, providing excellent efficacy and safety in prevention and treatment of migraine, transforming the clinical management of this condition.
Beyond migraine, CGRP plays important roles in cardiovascular physiology. In shock states, compensatory CGRP release may help maintain perfusion of vital organs, while excessive vasodilation may contribute to hypotension. In chronic conditions like atherosclerosis, hypertension, and heart failure, CGRP signaling may be disrupted, and loss of its protective function can exacerbate disease progression, making CGRP modulation a potential therapeutic avenue.
In oncology, aberrant CALCA expression and methylation patterns may serve as cancer biomarkers. Additionally, calcitonin analogs have long been used to inhibit bone resorption in osteoporosis and Paget's disease. However, systemic long-term CGRP blockade requires caution due to potential impacts on cardiovascular protection, immune surveillance, and bone metabolism. Future research aims to clarify the precise roles of CALCA-derived peptides in specific disease microenvironments and develop tissue-targeted modulation strategies.
References